• 1
    Piccini JP, Hernandez AF, Zhao X, Patel MR, Lewis WR, Peterson ED, Fonarow GC, Get With The Guidelines Steering Committee and Hospitals. Quality of care for atrial fibrillation among patients hospitalized for heart failure. J Am Coll Cardiol 2009; 54: 12809.
  • 2
    Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 113951.
  • 3
    Satoh T, Watanabe Y, Ikarashi N, Ito K, Sugiyama K. Effects of Kampo medicines on P-glycoprotein. Biol Pharm Bull 2009; 32: 201821.
  • 4
    Chen J, Raymond K. The role of CYP3A4 and p-glycoprotein in food–drug and herb–drug interactions. Pharmacist 2006; 25: 7328.
  • 5
    Robertson S, Penzak S. Drug Interactions. In:AtkinsonAJJr, AbernethyDR, DanielsCE, DedrickR, MarkeySP, eds. Principles of Clinical Pharmacology 2nd edn. San Diego, CA: Academic Press, 2007.
  • 6